RNA Interference Blocks Breast Cancer Growth

Share this content:

(ChemotherapyAdvisor) – Treating breast cancer using RNA interference could become a reality, according to researchers in the Program in Cellular and Molecular Medicine at Boston Children's Hospital and the Immune Disease Institute (PCMM/IDI). The study, entitled “Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2-positive Breast Cancer Growth and Metastasis,” was published April 20 in Science Translational Medicine

In this study, researchers bound siRNAs capable of silencing PLK1 (an enzyme that promotes cell division) to protamine, a peptide that shrink-wraps DNA in sperm cells. Attachment of protamine to an antibody fragment (called ScFv) against HER2 created the delivery package addressed directly to breast cancer cells with HER2 on their surface.

“Once in the tumors, the siRNAs were absorbed into tumor cells, where they turned off PLK1, retarding tumor growth and suppressing metastasis compared to untreated controls or those that received naked siRNAs. The team found no evidence of inflammation or toxicity in the liver, kidneys, or bloodstream, indicating that the siRNAs were silencing PLK1 only in their intended targets, the breast cancer cells,” the authors wrote.

Says Judy Lieberman, MD, PhD, senior investigator, Immune Disease Institute and Program in Cellular and Molecular Medicine: "The platform could be used to target siRNAs therapeutically to any cell for which we have a cell surface marker to target. We have also used it to target lymphocytes, suggesting it could be useful against lymphomas and leukemias and as a way of countering organ rejection."

Press Release


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs